Please login to the form below

Not currently logged in
Email:
Password:

cancer immunotherapies

This page shows the latest cancer immunotherapies news and features for those working in and with pharma, biotech and healthcare.

AZ signs $20m deal with Seres for microbiome project

AZ signs $20m deal with Seres for microbiome project

AstraZeneca is funding a research project at Seres Therapeutics to explore how the bacteria in the gut can affect – and possible enhance – the effect of cancer immunotherapies. ... improve the clinical outcomes of metastatic melanoma patients treated

Latest news

  • Merck puts prostate cancer firmly in Keytruda’s sights Merck puts prostate cancer firmly in Keytruda’s sights

    That combination has made prostate cancer an enticing target for drug developers and in particular those working on cancer immunotherapies, but both PD-1 and PD-L1 checkpoint inhibitors have largely ... prostate cancer, which is considered a cold tumour

  • Bicycle Therapeutics to tackle AMR with government funding Bicycle Therapeutics to tackle AMR with government funding

    Bicycle’s main focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates), aimed at developing novel cancer immunotherapies to harness innate immune activators and T-cell ... modulators. The company’s lead

  • Moderna CEO makes case for firm’s lofty valuation Moderna CEO makes case for firm’s lofty valuation

    For many analysts however, the results of Moderna’s personalised cancer vaccines, cancer immunotherapies and systemic therapeutics will be the best as a yardstick for mRNA’s potential as a new ... studies of candidates for respiratory syncytial virus

  • NICE lung cancer backing for Keytruda is biggest expansion yet NICE lung cancer backing for Keytruda is biggest expansion yet

    cell lung cancer (NSCLC) patients in combination with chemotherapy for up to two years. ... The ruling confirms Keytruda's dominance among PD-1/PD-L1 immunotherapies in treating lung cancer in England, as in other markets.

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    two primary endpoints in the MYSTIC trial of Imfinzi plus AZ’s experimental CTLA4 inhibitor tremelimumab in first-line lung cancer treatment. ... Now, the company has added to the options at its disposal as it tries to bring forward combinations of

More from news
Approximately 22 fully matching, plus 81 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies. ... Precision cancer treatment. The shift towards immunotherapies has been accompanied by another key trend – targeting

  • Deal Watch January 2018

    Back in June 2015 Celgene and Juno announced a ten-year collaboration to combine their respective immunology expertise to develop new immunotherapies for cancer and autoimmune diseases based on T cell ... The incoming cash will be used by Immunomedics to

  • Deal Watch November 2015 Deal Watch November 2015

    A package deal covering up to five cancer immunotherapies, the headline value was $1.56bn with an upfront fee of $60m; the subsequent milestone terms per product could reach in excess ... Sanofi will gain access to BioNTech's mRNA formulation technology

  • Pharma deals in June 2015 Pharma deals in June 2015

    Immune modulators in cancer and beyond. Both Juno Therapeutics and Celgene have had a busy month in forming alliances in the immunotherapy area. ... Near the close of the month, Juno and Celgene announced a $1bn, 10-year collaboration to develop novel

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    Phase 3 immuno-oncology treatment for prostate cancer. 975. Intrexon / Merck Serono. ... 825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    Gaweco will lead Apeiron’s immuno-oncology programmes, overseeing the discovery, clinical and medical functions of the company’s new molecular entities pipeline of cancer immunotherapies. ... His outreach into the worldwide pharmaceutical markets

  • Targovax strengthens board of directors Targovax strengthens board of directors

    of our novel and complementary portfolio of cancer immunotherapies.”.

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    He said: “ Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer. ... Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral

  • Merck’s Richard Murray joins Jounce as CEO Merck’s Richard Murray joins Jounce as CEO

    pembrolizumab. This experience will benefit Jounce, a Cambridge, Massachusetts-based company that specialises in cancer immunotherapies. ... The new CEO sees potential in Jounce, however, with the prospect of cancer immunotherapies an appetising one for

  • Bruno Strigini leaves Merck & Co for Novartis Bruno Strigini leaves Merck & Co for Novartis

    These sales made Novartis the third largest pharma company in cancer for the year. ... The area of anti-PD1 cancer immunotherapies looks to be an important one for many companies, with Bristol-Myers Squibb, Roche and AstraZeneca all developing their own

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

    With the promise of using the body’s own immune system to fight cancer,  immunotherapy has received significant interest from the scientific community,  bringing hope to patients across many cancer indications. ... The first generation of agents has

  • Immuno-oncology; bringing patients closer to treatment

    cure; immunotherapies offer positive news for all stakeholders involved in the fight against cancer. ... Immunotherapies can treat head, neck, lung, prostate, renal, multiple myeloma, AML, ALL and kidney cancer.

  • Immunotherapy in oncology

    We are certainly some distance away from the Obama administration’s moon-shot of curing cancer… or are we? ... Three states of interaction exist in immunoediting;. Elimination, in which the immune response eradicates cancer cells.

  • Focus on immunotherapies: special magazine from Blue Latitude Health

    In this supplementary issue, we’re taking a special look at immunotherapies, and more specifically, the growing buzz around “immuno-oncology” therapies. ... What new immunotherapies in oncology mean for cancer patients and the doctors who would

  • Blue Latitude Health

    Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships. ... Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving.

More from PMHub
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics